These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 36039036)

  • 1. Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study.
    Chanchlani N; Lin S; Auth MK; Lee CL; Robbins H; Looi S; Murugesan SV; Riley T; Preston C; Stephenson S; Cardozo W; Sonwalkar SA; Allah-Ditta M; Mansfield L; Durai D; Baker M; London I; London E; Gupta S; Di Mambro A; Murphy A; Gaynor E; Jones KDJ; Claridge A; Sebastian S; Ramachandran S; Selinger CP; Borg-Bartolo SP; Knight P; Sprakes MB; Burton J; Kane P; Lupton S; Fletcher A; Gaya DR; Colbert R; Seenan JP; MacDonald J; Lynch L; McLachlan I; Shields S; Hansen R; Gervais L; Jere M; Akhtar M; Black K; Henderson P; Russell RK; Lees CW; Derikx LAAP; Lockett M; Betteridge F; De Silva A; Hussenbux A; Beckly J; Bendall O; Hart JW; Thomas A; Hamilton B; Gordon C; Chee D; McDonald TJ; Nice R; Parkinson M; Gardner-Thorpe H; Butterworth JR; Javed A; Al-Shakhshir S; Yadagiri R; Maher S; Pollok RCG; Ng T; Appiahene P; Donovan F; Lok J; Chandy R; Jagdish R; Baig D; Mahmood Z; Marsh L; Moss A; Abdulgader A; Kitchin A; Walker GJ; George B; Lim YH; Gulliver J; Bloom S; Theaker H; Carlson S; Cummings JRF; Livingstone R; Beale A; Carter JO; Bell A; Coulter A; Snook J; Stone H; Kennedy NA; Goodhand JR; Ahmad T;
    Aliment Pharmacol Ther; 2022 Oct; 56(8):1250-1263. PubMed ID: 36039036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA; Heap GA; Green HD; Hamilton B; Bewshea C; Walker GJ; Thomas A; Nice R; Perry MH; Bouri S; Chanchlani N; Heerasing NM; Hendy P; Lin S; Gaya DR; Cummings JRF; Selinger CP; Lees CW; Hart AL; Parkes M; Sebastian S; Mansfield JC; Irving PM; Lindsay J; Russell RK; McDonald TJ; McGovern D; Goodhand JR; Ahmad T;
    Lancet Gastroenterol Hepatol; 2019 May; 4(5):341-353. PubMed ID: 30824404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
    Chanchlani N; Lin S; Bewshea C; Hamilton B; Thomas A; Smith R; Roberts C; Bishara M; Nice R; Lees CW; Sebastian S; Irving PM; Russell RK; McDonald TJ; Goodhand JR; Ahmad T; Kennedy NA;
    Lancet Gastroenterol Hepatol; 2024 Jun; 9(6):521-538. PubMed ID: 38640937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-drug antibodies against anti-TNF in patients with inflammatory bowel disease: an evaluation of possible strategies.
    Anjie SI; Hanzel J; Gecse KB; D'Haens GR; Brandse JF
    Scand J Gastroenterol; 2024; 59(2):169-175. PubMed ID: 37961895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease.
    Strik AS; van den Brink GR; Ponsioen C; Mathot R; Löwenberg M; D'Haens GR
    Aliment Pharmacol Ther; 2017 Apr; 45(8):1128-1134. PubMed ID: 28230306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
    Sazonovs A; Kennedy NA; Moutsianas L; Heap GA; Rice DL; Reppell M; Bewshea CM; Chanchlani N; Walker GJ; Perry MH; McDonald TJ; Lees CW; Cummings JRF; Parkes M; Mansfield JC; Irving PM; Barrett JC; McGovern D; Goodhand JR; Anderson CA; Ahmad T;
    Gastroenterology; 2020 Jan; 158(1):189-199. PubMed ID: 31600487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease.
    Gil-Candel M; Gascón-Cánovas JJ; Urbieta-Sanz E; Rentero-Redondo L; Onteniente-Candela M; Iniesta-Navalón C
    Int J Clin Pharm; 2020 Apr; 42(2):500-507. PubMed ID: 32006141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease.
    Mahmoud R; Schultheiss HP; Louwers J; van der Kaaij M; van Hellemondt B; Mahmmod N; van Boeckel P; Jharap B; Fidder H; Oldenburg B
    Clin Gastroenterol Hepatol; 2022 Nov; 20(11):2577-2587.e6. PubMed ID: 35101632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients With Low Drug Levels or Antibodies to a Prior Anti-Tumor Necrosis Factor Are More Likely to Develop Antibodies to a Subsequent Anti-Tumor Necrosis Factor.
    Vande Casteele N; Abreu MT; Flier S; Papamichael K; Rieder F; Silverberg MS; Khanna R; Okada L; Yang L; Jain A; Cheifetz AS
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):465-467.e2. PubMed ID: 33421628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable Outcomes and Anti-TNF Durability After Addition of an Immunomodulator for Anti-Drug Antibodies in Pediatric IBD Patients.
    Colman RJ; Portocarrero-Castillo A; Chona D; Hellmann J; Minar P; Rosen MJ
    Inflamm Bowel Dis; 2021 Mar; 27(4):507-515. PubMed ID: 32426829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
    Chanchlani N; Lin S; Chee D; Hamilton B; Nice R; Arkir Z; Bewshea C; Cipriano B; Derikx LAAP; Dunlop A; Greathead L; Griffiths RL; Ibraheim H; Kelleher P; Kok KB; Lees CW; MacDonald J; Sebastian S; Smith PJ; McDonald TJ; Irving PM; Powell N; Kennedy NA; Goodhand JR; Ahmad T
    J Crohns Colitis; 2022 Mar; 16(3):389-397. PubMed ID: 34473254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases.
    Sasson AN; Ananthakrishnan AN
    Dig Dis Sci; 2022 Jul; 67(7):3124-3128. PubMed ID: 34117949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.
    Battat R; Lukin D; Scherl EJ; Pola S; Kumar A; Okada L; Yang L; Jain A; Siegel CA
    Inflamm Bowel Dis; 2021 Aug; 27(9):1443-1451. PubMed ID: 33252119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infections in inflammatory bowel disease patients on immunomodulator and biologic therapy are not associated with high serum drug levels.
    Gazelakis K; Chu I; Martin C; Sparrow MP
    Intern Med J; 2024 Jan; 54(1):139-148. PubMed ID: 37151186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of anti-TNF use and associated treatment outcomes in inflammatory bowel disease patients: results from an analysis of Dutch health insurance claims data.
    Bots SJA; Hoekman DR; Benninga MA; Ponsioen CY; D'Haens GR; Löwenberg M
    Neth J Med; 2017 Dec; 75(10):432-442. PubMed ID: 29256410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.